InvestorsHub Logo
Followers 128
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

Re: None

Wednesday, 07/26/2017 8:15:19 AM

Wednesday, July 26, 2017 8:15:19 AM

Post# of 660

Ladenburg Thalmann raised its price target on Axsome Therapeutics (NASDAQ: AXSM) to $31.00 (from $28.00) while maintaining a Buy rating. July 26, 2017 6:48 AM EDT
https://www.streetinsider.com/Analyst+Comments/Axsome+Therapeutics+(AXSM)+PT+Raised+to+%2431+at+Ladenburg+Thalmann/13129605.html

Analyst Matt Kaplan comments "Interim Phase 3 data for CRPS is expected in 4Q17, with AXS-02 potentially being initially launched in the US in 2019, and other indications following in later years. We estimate AXS-02 can achieve $150 million in revenue in CRPS, with other pain indications also adding materially. At peak, we estimate AXS-02 can reach $600 million."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXSM News